Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report

Steven Z. Pavletic(National Institutes of Health), Paul J. Martin(University of Washington), Stephanie J. Lee(Dana-Farber Cancer Institute), Sandra A. Mitchell(National Cancer Institute), David A. Jacobsohn(Northwestern Memorial Hospital), Edward W. Cowen(National Institutes of Health), Maria L. Turner(National Cancer Institute), Görgün Akpek(University of Maryland, Baltimore), Andrew L. Gilman(University of North Carolina at Chapel Hill), George B. McDonald(University of Washington), Mark Schubert(Fred Hutch Cancer Center), Ann Berger(National Institutes of Health Clinical Center), Peter Bross(United States Food and Drug Administration), Jason W. Chien(University of Washington), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), James P. Dunn(Johns Hopkins University), Jane M. Fall‐Dickson(National Institutes of Health), Ann T. Farrell(United States Food and Drug Administration), Mary E.D. Flowers(University of Washington), Hildegard Greinix(Medical University of Vienna), Steven Hirschfeld(United States Food and Drug Administration), Lynn H. Gerber(National Institutes of Health Clinical Center), Stella Kim(The University of Texas MD Anderson Cancer Center), Robert Knobler(Medical University of Vienna), Peter A. Lachenbruch(United States Food and Drug Administration), Frederick W. Miller(National Institute of Environmental Health Sciences), Barbara B. Mittleman(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Esperanza B. Papadopoulos(Memorial Sloan Kettering Cancer Center), Susan K. Parsons(Tufts Medical Center), Donna Przepiorka(University of Tennessee Health Science Center), M. Robinson(National Eye Institute), Michael E. Ward(National Institute of Arthritis and Musculoskeletal and Skin Diseases), Bryce B. Reeve(National Institutes of Health), Lisa G. Rider(National Institutes of Health), Howard M. Shulman(University of Washington), Kirk R. Schultz(University of British Columbia), Daniel Weisdorf(University of Minnesota System), Georgia B. Vogelsang(Johns Hopkins University)
Biology of Blood and Marrow Transplantation
March 1, 2006
Cited by 565Open Access
Full Text

Abstract

In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus Response Criteria Working Group recommended several measures to document serial evaluations of chronic GVHD organ involvement. Provisional definitions of complete response, partial response, and progression were proposed for each organ and for overall outcome. Based on publications over the last 9 years, the 2014 Working Group has updated its recommendations for measures and interpretation of organ and overall responses. Major changes include elimination of several clinical parameters from the determination of response, updates to or addition of new organ scales to assess response, and the recognition that progression excludes minimal, clinically insignificant worsening that does not usually warrant a change in therapy. The response definitions have been revised to reflect these changes and are expected to enhance reliability and practical utility of these measures in clinical trials. Clarification is provided about response assessment after the addition of topical or organ-targeted treatment. Ancillary measures are strongly encouraged in clinical trials. Areas suggested for additional research include criteria to identify irreversible organ damage and validation of the modified response criteria, including in the pediatric population.


Related Papers